^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Non Small Cell Lung Cancer

    Related cancers:
    Apply
    Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors (NCT07645742)
    Phase N/A
    West Virginia University
    Not yet recruiting
    Last update posted :
    06/12/2026
    Initiation :
    07/01/2026
    Primary completion :
    02/01/2029
    Completion :
    02/01/2029
    MSI
    |
    MSI-H/dMMR
    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer (NCT07476287)
    Phase 2
    Pfizer
    Not yet recruiting
    Last update posted :
    03/17/2026
    Initiation :
    05/15/2026
    Primary completion :
    03/19/2028
    Completion :
    03/19/2031
    EGFR
    |
    EGFR mutation
    Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) (NCT07472478)
    Phase 2
    Guangdong Provincial People's Hospital
    Not yet recruiting
    Last update posted :
    03/16/2026
    Initiation :
    03/15/2026
    Primary completion :
    12/31/2027
    Completion :
    03/31/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • paclitaxel • Anfangning (garsorasib) • Idafang (ivonescimab)
    BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT07469774)
    Phase 1/2
    Biocity Biopharmaceutics Co., Ltd.
    Not yet recruiting
    Last update posted :
    03/13/2026
    Initiation :
    03/17/2026
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    EGFR • BRAF • ALK • MET • NTRK
    |
    MET exon 14 mutation
    |
    Keytruda (pembrolizumab)
    A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks (PRO-ACTIVE) (NCT07469709)
    Phase N/A
    Fondazione del Piemonte per l'Oncologia
    Recruiting
    Last update posted :
    03/13/2026
    Initiation :
    02/01/2024
    Primary completion :
    05/01/2027
    Completion :
    12/31/2027
    BRCA
    A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China (NCT07198620)
    Phase N/A
    Guangdong Association of Clinical Trials
    Not yet recruiting
    Last update posted :
    09/30/2025
    Initiation :
    10/01/2025
    Primary completion :
    06/01/2026
    Completion :
    12/01/2026
    KRAS
    |
    Dupert (fulzerasib)
    A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (NCT07190248)
    Phase 3
    Merck Sharp & Dohme LLC
    Not yet recruiting
    Last update posted :
    09/24/2025
    Initiation :
    10/27/2025
    Primary completion :
    12/07/2029
    Completion :
    08/06/2032
    PD-L1 • KRAS
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)
    Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (NCT07190027)
    Phase 1/2
    First Affiliated Hospital of Wenzhou Medical Un...
    Not yet recruiting
    Last update posted :
    09/24/2025
    Initiation :
    11/01/2025
    Primary completion :
    11/01/2025
    Completion :
    11/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC (SURGAN-ICI) (NCT07177105)
    Phase 2
    Jianxing He
    Not yet recruiting
    Last update posted :
    09/16/2025
    Initiation :
    09/10/2025
    Primary completion :
    10/01/2028
    Completion :
    10/01/2030
    PD-L1
    |
    carboplatin • Tyvyt (sintilimab)
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (NCT07174908)
    Phase 3
    InxMed (Shanghai) Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/16/2025
    Initiation :
    09/01/2025
    Primary completion :
    09/01/2028
    Completion :
    09/01/2030
    KRAS
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)
    Immune Response Under Immunotherapy in Lung Cancer: Study of Sputum Samples (RICEPS-2) (NCT07163507)
    Phase N/A
    University Hospital, Tours
    Not yet recruiting
    Last update posted :
    09/09/2025
    Initiation :
    10/01/2025
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    PD-L1
    AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment (AGA TKI NSCLC) (NCT07158840)
    Phase 2
    Akeso
    Not yet recruiting
    Last update posted :
    09/08/2025
    Initiation :
    09/05/2025
    Primary completion :
    09/01/2028
    Completion :
    06/01/2029
    PD-L1
    |
    Idafang (ivonescimab)